Luminex Raises $83 Mil In Public Stock Offering

CEO SUMMARY: During the past year, Luminex Corporation moved swiftly to push its LabMAP™ multiplex testing technology into the bioassay marketplace. It found high interest among companies in the pharmaceutical, diagnostics, and bioresearch industries. Luminex executives say that a number of companies are working to have FDA-approved diagnostic test kits available for laboratories by year’s …

Luminex Raises $83 Mil In Public Stock Offering Read More »

To access this post, you must purchase The Dark Report.

Luminex Raises $83 Mil In Public Stock Offering

Multiplex testing technology finds ready acceptance with diagnostics & drug firms

Comments

TABLE OF CONTENTS

Need A Group Membership? Company Discounts are Available!

You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

You have read 0 of 1 of your complimentary articles this month